Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€112.20

€112.20

0.360%
0.4
0.360%
€124.47
 
11:31 / Tradegate WKN: A0YD8Q / Symbol: MRK / Name: Merck & Co / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Merck & Co. Inc. Stock

The Merck & Co. Inc. stock is trending slightly upwards today, with an increase of €0.40 (0.360%) compared to yesterday's price.
With 25 Buy predictions and 1 Sell predictions Merck & Co. Inc. is one of the favorites of our community.
With a target price of 124 € there is a slightly positive potential of 10.52% for Merck & Co. Inc. compared to the current price of 112.2 €.
So far the community has only identified positive things for Merck & Co. Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Merck & Co. Inc. in the next few years

Pros
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Merck & Co. Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Merck & Co. Inc. 0.360% -0.710% -5.734% 14.784% 13.503% 72.000% 56.058%
Elanco Animal Health Inc. 1.520% -0.955% -3.714% 65.451% 7.396% -48.520% -
Pfizer Inc. 0.200% -1.541% -0.390% -32.336% -2.107% -14.862% -26.861%
Biogen Inc. 0.400% -4.179% -0.689% -18.250% -14.419% -8.584% -29.542%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-16

The financial statements of Merck & Co, a prominent player in the pharmaceutical industry, reflect a company that is performing relatively well in terms of operational efficiency, profitability, and growth. Although Merck faces risks, common to pharmaceutical companies, including R&D expenses, regulatory compliance, and competition, the company appears to be maintaining stable growth over the past years. The following analysis discusses both the positives and negatives associated with the company's financials.

*Pros: *

Revenue Growth: Merck's total revenue has grown consistently over the past three years, indicating a successful expansion and growth strategy. This points to a strong product pipeline and competent market positioning, which are essential factors for success in the pharmaceutical industry.

Comments

Prediction Sell
Perf. (%) 1.35%
Target price 95.150
Change
Ends at 11.03.25

Merck & Co., Inc. (NYSE: MRK) was downgraded by analysts at Societe Generale from a "hold" rating to a "sell" rating. They now have a $104.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -3.81%
Target price 124.929
Change
Ends at 28.02.25

Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -3.16%
Target price 125.780
Change
Ends at 14.02.25

Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Show more